Age specific and attributable risks of familial prostate carcinoma from the family-cancer database

Cancer

Volumn 95, Issue 6, 2002, Pages 1346-1353

  Hemminki, Kari ^a,b   Czene, Kamila ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b CNT Novum   (Sweden)

Author keywords

Age of onset; Brothers; Familial risk; Heritable effect; Recessive effect

Indexed keywords

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; CANCER INCIDENCE; CANCER REGISTRY; CANCER RISK; CANCER SCREENING; CHILD; CONTROLLED STUDY; FAMILIAL CANCER; FAMILY HISTORY; GENETIC RISK; HUMAN; INFANT; INHERITANCE; MAJOR CLINICAL STUDY; MALE; ONSET AGE; PATIENT COUNSELING; PRIORITY JOURNAL; PROSTATE CANCER;

AGE FACTORS; DATABASES, FACTUAL; FAMILY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; RISK FACTORS; SWEDEN;

EID: 0037105581     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.10819     Document Type: Article

References (51)

1. Genetic epidemiology of prostate cancer
2. Familial prostate cancer from the family-cancer database
3. Relatives of prostate cancer patients have an increased risk of prostate and stomach cancers: A population-based, cancer registry study in Finland
4. Systematic population-based assessment of cancer risk in first-degree relatives of cancer probands
5. Age-specific familial risks in common cancers of the offspring
6. Familial cancers in a nation-wide family-cancer database: Age distribution and prevalence
7. Modification of cancer risks in off-spring by sibling and parental cancers from 2,112,616 nuclear families
8. Sibling risks in cancer: Clues to recessive or X-linked genes?
9. Evidence of an X-linked or recessive genetic component to prostate cancer risk
10. Heredity and prostate cancer: A study of world war II veteran twins
11. The genetic epidemiology of cancer: Interpreting family and twin studies and their implications for molecular genetic approaches
12. Re: Genetic epidemiology of cancer: Interpreting family and twin studies and their implications for molecular genetic approaches
13. Family history facilitates the early diagnosis of prostate carcinoma
14. Cancer in twins: Genetic and nongenetic familial risk factors
15. Environmental and heritable factors in the causation of cancer
16. Mendelian inheritance of familial prostate cancer
17. Hereditary prostate cancer: Epidemiologic and clinical features
18. Risk of cancer in relatives of prostate cancer probands
19. Segregation analysis of prostate cancer in Sweden: Support for dominant inheritance
20. Evidence for autosomal dominant inheritance of prostate cancer
21. Autosomal dominant inheritance of prostate cancer: A confirmatory study
22. Evidence for a prostate cancer susceptibility locus on the X chromosome
23. Evaluation of linkage and association of HPC2/ELAC2 in patients with familial or sporadic prostate cancer
24. In Swedish families with hereditary prostate cancer, linkage to the HPC1 locus on chromosome 1q24-25 is restricted to families with early-onset prostate cancer
25. Evidence for a rare prostate cancer-susceptibility locus at chromosome 1p36
26. Linkage analyses at the chromosome 1 loci 1q24-25 (HPC1), 1q42.2-43 (PCAP), and 1p36 (CAPB) in families with hereditary prostate cancer
27. Role of HPC2/ELAC2 in hereditary prostate cancer
28. Two percent of Finnish prostate cancer patients have a germ-line mutation in the hormone-binding domain of the androgen receptor gene
29. Cancer risks in first generation immigrants to Sweden
30. Cancer risks in second-generation immigrants to Sweden
31. Comparison of self-reported and database-linked family history of cancer data in a case-control study
32. Accuracy of family history of cancer as reported by men with prostate cancer
33. Genetic epidemiology: Science and ethics on familial cancers
34. The nation-wide Swedish Family-Cancer Database: Updated structure and familial rates
35. Health technology assessment and screening in Sweden
36. Proportion of disease caused or prevented by a given exposure, trait or intervention
37. Incidence trends and risk factors of carcinoid tumors
38. Detection of subclinical cancers by prostate-specific antigen screening in symptomatic men from high-risk prostate cancer families
39. Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging
40. Prostate cancer screening within a prostate specific antigen range of 3.0 to 3.9 ng./mL: A comparison of digital rectal examination and free prostate specific antigen as supplemental screening tests
41. Large-scale randomized prostate cancer screening trials: Program performances in the European randomized screening for prostate cancer trial and the prostate, lung, colorectal and ovary cancer trial
42. Attributable risks for familial breast cancer by proband status and morphology: A nation-wide epidemiological study from Sweden